The human amnion is a major intrauterine source of prostaglandin (PG) E 2 , a potent mediator of uterine contractions and cervical ripening. During parturition, inflammatory cytokines promote PGE 2 production through increased prostaglandin-endoperoxide synthase-2 (PTGS2, also known as cyclooxygenase-2) expression. This is mediated, in part, through activation of the transcription factor nuclear factor kappa B (NFkappaB). Prostaglandin E synthase (PTGES, also known as microsomal PGE synthase-1) acts downstream of PTGS2 and is inducibly expressed in most systems. We hypothesized that NFkappaB might regulate cytokine-induced PTGES expression in amnion cells. With amnion mesenchymal cells, we found that proinflammatory cytokines coordinately upregulated PTGS2 and PTGES mRNA expression. In parallel, increased expression of the PTGS2 and PTGES proteins was observed. In comparison, the expression of two other PGE synthases (PTGES2 and PTGES3) was unmodified. PTGES induction was blocked both in the presence of pharmacological NFkappaB inhibitors and following adenovirus-mediated overexpression of a dominant-negative NFkappaB pathway protein. In cells transiently transfected with a luciferase reporter bearing a portion (À597/þ33) of the human PTGES gene promoter, interleukin-1beta (IL1B) produced a moderate increase in luciferase activity; this effect was abrogated in the presence of an indirect NFkappaB inhibitor . Finally, a kappaB-like regulatory element was identified that, when mutated, markedly attenuated IL1B-responsive PTGES promoter activity. In conclusion, our results support a role for NFkappaB in cytokine-induced PTGES expression in amnion mesenchymal cells in vitro. By coordinately regulating PTGS2 and PTGES, NFkappaB may contribute to an inducible PGE 2 biosynthesis pathway during human parturition.
INTRODUCTION
The generation of prostaglandins (PGs) by amnion and decidual tissues is fundamental to both the onset and continuance of human labor. Uterotonic eicosanoids such as PGE 2 accumulate in amniotic fluid with advancing gestation [1] , and the enzymatic pathways responsible for PGE 2 production are active in amnion cells prior to the onset of active labor [2] . PGs generated toward the end of gestation are thought to contribute to early labor-associated events, such as myometrial activation and cervical ripening [3] . During spontaneous active labor, a surge in PG production accompanies a series of biochemical events resembling a localized, acute inflammatory response (reviewed in [4] ).
PG production requires the coordination of three major enzymatic reactions. In this pathway, arachidonic acid liberated from intracellular membranes by phospholipases is converted to intermediates by isoforms of prostaglandin-endoperoxide synthase (PTGS, also known as prostaglandin G/H synthase or cyclooxygenase); these are subsequently isomerized by terminal PG synthases to form active PGs. Two wellcharacterized PTGS isoforms, PTGS1 and PTGS2, catalyze the committing and rate-limiting step in this cascade. Whereas PTGS1 is constitutively expressed and contributes to immediate, low-amplitude PG release, the PTGS2 isoform is required for high-amplitude, delayed PG production [5] . In the context of parturition, copious PG production is associated with increased de novo expression of PTGS2 [6, 7] .
For biosynthesis of PGE 2 , the major PG released by human amnion, several distinct gene products bearing terminal PGE isomerase activity have been described, including prostaglandin E synthase (PTGES, also known as microsomal PGE synthase-1), PTGES2 (also known as microsomal PGE synthase-2), and PTGES3 (also known as cytosolic PGE synthase) [8, 9] . Among these, PTGES is distinguished in that 1) it is upregulated in response to proinflammatory stimuli in many systems [10] [11] [12] , including intrauterine cells [13, 14] ; 2) it exhibits catalytic efficiency exceeding that of other PGE isomerases [15] ; and 3) it is functionally coupled with PTGS2, an assertion that is supported by both biochemical [16] and gene deletion studies [17] [18] [19] . Collectively, such observations suggest that PTGH2 and PTGES comprise an inducible pathway for inflammatory PGE 2 release.
Given that both PTGES and PTGS2 are induced in response to common proinflammatory stimuli, we hypothesized that the genes encoding these proteins might share common regulatory mechanisms. In the present study, we addressed whether the transcription factor nuclear-factor kappa B (NFjB), a master transcription factor for inflammatory gene expression and a major regulator of PTGS2 transcription, might also govern the expression of PTGES in amnion cells in vitro.
MATERIALS AND METHODS

Materials
Recombinant human interleukin-1b (IL1B) and tumor necrosis factor (TNF) alpha were purchased from R&D Systems (Minneapolis, MN). The NFjB inhibitors MG-132, SN50, and SN50M were obtained from BIOMOL International (Plymouth Meeting, PA). The Dual-Luciferase Reporter Assay System and the Renilla luciferase control expression vector (pRL-SV40) were obtained from Promega (Madison, WI). A luciferase reporter plasmid (pGL2-651) containing a region of the human PTGES gene promoter (À651/À20 relative to the translation start site, À597/þ33 in relation to the transcription start site) was generously donated by Ralf Morgenstern (Karolinska Institute, Stockholm, Sweden) and has been described previously [11] . The QuikChange Site-Directed Mutagenesis Kit was obtained from Stratagene (La Jolla, CA). Arachidonic acid, PGE 2 ELISA kits, and antibodies against PTGES (catalog numbers 160140 and 10004350), PTGES2 (catalog number 160145), and PTGES3 (catalog number 160150) were purchased from Cayman Chemical Company (Ann Arbor, MI). TRIzol reagent, cell culture media and sera, oligonucleotide primers, reagents for RT-PCR, Prolong Gold antifade mounting reagent, and Alexa Fluor-conjugated secondary antibodies (used in immunofluorescence experiments) were purchased from Invitrogen (Carlsbad, CA). SuperSignal chemiluminescent detection reagents were obtained from Pierce Biotechnology (Rockford, MA). Antibodies against PTGS2, inhibitory factor jBa (IjBa, also known as nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha, NFKBIA), inhibitory factor jBb (IjBb, also known as nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor beta, NFKBIB), IjB kinase a (IKKa, also known as conserved helixloop-helix ubiquitous kinase, CHUK), and NFjB subunit p65 (also known as reticuloendotheliosis viral oncogene homolog A, RELA), were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was purchased from Chemicon International (Temecula, CA). Antibodies recognizing phosphorylated forms of NFKBIA (IjBa; Ser32), RELA (p65; Ser536), and CHUK/IKBKB (IKKa/ IKKb; Ser180/Ser181) were from Cell Signaling Technology (Beverly, MA). Assays-on-Demand gene expression target assay mixtures (assay numbers Hs00610420_m1, Hs00228159_m1, Hs00832847_gH, Hs00153133_m1, and Hs99999905_m1 for PTGES, PTGES2, PTGES3, PTGS2, and GAPDH, respectively) and TaqMan Universal Master Mix were obtained from Applied Biosystems (Foster City, CA). ViraDuctin reagent and adenovirus particles expressing either recombinant E. coli b-galactosidase (Ad-lacZ, catalog number ADV-002) or a dominant-negative form of the human NFKBIA (IjBa protein [Ad-DN-NFKBIA], catalog number ADV-302) were purchased from Cell Biolabs (San Diego, CA). The b-galactosidase reporter gene histochemical staining kit, collagenase A, trypsin inhibitor, and monoclonal anti-vimentin and anti-cytokeratin antibodies were purchased from Sigma (St. Louis, MO); all other reagents unless otherwise specified also were obtained from Sigma.
Isolation of Amnion Mesenchymal Cells
Fetal membranes were collected at the time of uncomplicated scheduled cesarean delivery at term in the absence of labor or membrane rupture. There was no clinical evidence of infection in any of these subjects. Informed consent was obtained by a protocol approved by the Institutional Review Board of The Ohio State University (Columbus, OH).
Human amnion mesenchymal cells were obtained from the reflected fetal membranes following blunt dissection of the choriodecidua and digestion with 1 mg/ml of collagenase A, as previously described [20, 21] . Cells were seeded onto culture dishes coated with 0.1% (w/v) type I collagen and grown in Dulbecco modified Eagle medium (4500 mg/L of D-glucose) supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 50 lg/ml of gentamicin sulfate, 0.5 lg/ml of amphotericin B, and 10% (v/v) fetal bovine serum. Cultures attained confluence within 4-7 days and were subsequently expanded and plated for experiments at the lowest possible passage number (between the first and third passages for the experiments described). In some experiments, cultures enriched for amnion epithelial cells were derived simultaneously with mesenchymal cells with a series of incubations in 0.4% (w/v) trypsin [22] ; these were grown in primary culture as described previously [23] .
Immunofluorescence
Immunolabeling of cultured cells was performed as described previously [23] with antibodies directed against NFjB subunit RELA (p65, sc-8008; Santa Cruz), vimentin (Sigma), or cytokeratin (Sigma). In control experiments, an equivalent concentration of isotype-specific normal mouse immunoglobulin G (IgG) or an irrelevant antibody (anti-FLAG epitope) was substituted for the primary antibody; these controls exhibited only faint, nonspecific staining in all cases. After stringent washing in PBS, the coverslips were exposed to fluorophore-conjugated secondary antibodies (Molecular Probes). Nuclei were counterstained with 5 lg/ml of 4 0 ,6-diamidino-2-phenylindole (Sigma). Cells were mounted with the ProLong Antifade kit (Molecular Probes) and visualized with conventional epifluorescence (Nikon Instruments, Melville, NY) or confocal laser scanning microscopy (Zeiss 510 META; Carl Zeiss Inc., Thornwood, NY).
Immunoblot Analysis
Cellular proteins were extracted as previously described [23] . Proteins (20 lg/lane) were resolved by SDS-PAGE and transferred to nitrocellulose. Immunoblotting was performed with antibodies directed against targets described in the text and figure legends in Tris-buffered saline (pH 8.0) containing 0.05% (v/v) Tween-20 and 5% (w/v) nonfat dry milk. Following exposure to horseradish peroxidase-conjugated secondary antibodies, chemiluminescent signals were detected with SuperSignal chemiluminescent detection reagents (Pierce). Immunoreactive proteins were visualized with the VersaDoc Imaging System and analyzed by Quantity One software (Bio-Rad, Hercules, CA).
RNA Isolation and Real-Time RT-PCR
Total RNA from cultured amnion mesenchymal cells was purified with TRIzol reagent (Invitrogen) according to the method of Chomczynski and Sacchi [24] . Complementary DNA was prepared from 2 lg of RNA with oligodT primers and SuperScript II RT (Invitrogen). For quantitative real-time RT-PCR, cDNA was amplified with Assays-on-Demand gene expression target assay primer/probe mixtures (Applied Biosystems) and detected with an ABI PRISM 7700 sequence detector (Applied Biosystems). Amplification mixtures contained 2.5 ll of the appropriate 203 target assay mixture, 1 ll of first-strand cDNA synthesis mixture (corresponding to 50 ng of reverse-transcribed RNA), 25 ll of 23 TaqMan Universal Master Mix (Applied Biosystems), and nuclease-free distilled, deionized water to a total volume of 50 ll. Amplification was performed over 40 cycles of denaturation at 958C for 15 sec and annealing/extension at 608C for 1 min. For each treatment condition, duplicate amplifications were performed. Fold change was computed relative to control by the 2 ÀDDCT method [25] . Samples were normalized to GAPDH expression, determined in parallel reactions.
Site-Directed Mutagenesis
In vitro mutagenesis was performed with the QuikChange Site-Directed Mutagenesis Kit (Stratagene), according to the manufacturer's instructions. Briefly, the supercoiled template plasmid (pGL2-651) was replicated in the presence of complementary mutagenic primers (sequences for the plus strand: 5 0 -CGA AAT CCC ATG TtA cAA GaC agT TTT GCC ACA TAG TCA CAG TCA CGG; lowercase letters refer to mutated oligonucleotides of a putative jB response element, 5 0 -GAAAAGTCCC). Subsequently, the methylated template plasmid was digested with the restriction endonuclease Dpn I, and the variant plasmid (pGL2-651 [mjB]) was transformed into chemically competent E. coli. The desired mutation was verified by sequence analysis (Plant-Microbe Genomics Facility, The Ohio State University, Columbus, OH).
Transient Transfection of Amnion Mesenchymal Cells
Transient transfections were performed in a 24-well tissue culture plate seeded at 4 3 10 4 cells per well. For each cotransfection, 0.7 lg of firefly luciferase reporter plasmid (pGL2-651 or pGL2-651 [mjB]), 0.1 lg of Renilla luciferase control plasmid (pRL-SV40), and 2.5 ll of LIPOFECTAMINE 2000 reagent (Invitrogen) were diluted into OPTI-MEM I Reduced Serum Medium (Invitrogen), according to the manufacturer's instructions. By this method, transfection efficiencies for individual amnion mesenchymal cell preparations ranged from 10% to 30%, as determined with a reporter plasmid expressing a variant of Aequorea victoria green fluorescent protein (pEGFP-N1; BD Biosciences Clontech, Mountain View, CA).
Luciferase assays were performed with the Dual-Luciferase Reporter Assay System (Promega) on either a Dynex MLX microplate luminometer (Dynex Technologies, Chantilly, VA) or a Wallac 1420 VICTOR 3 multilabel plate reader (PerkinElmer, Waltham, MA). Reporter activity was expressed as the ratio of firefly luciferase activity to Renilla luciferase activity.
Adenovirus-Mediated Gene Transfer to Amnion Mesenchymal Cells
All recombinant adenovirus particles were prepared by Cell Biolabs (San Diego, CA). Permission to use these vectors was granted by the Institutional
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Biosafety Committee of The Ohio State University. Preconfluent amnion mesenchymal cells were infected with adenoviral vectors (Ad-lacZ and Ad-DN-Ad-DN-NFKBIA, with a multiplicity of infection (MOI) of 1-1000 plaque-forming units per cell in the absence or presence of ViraDuctin (9 ll/10 6 cells). Cells were incubated for 48 h in the presence of viral particles prior to washing and exchange with fresh serum-containing medium. Following an additional 24-h incubation, cells were assessed for the expression and function of the transferred genes. All experiments were conducted with cells infected at an MOI of 500, which resulted in maximal expression levels 3 days after infection.
Staining for b-Galactosidase (lacZ) Reporter Gene Activity
Following infection with Ad-lacZ, cells were fixed in 2% (v/v) formaldehyde/0.2% (v/v) glutaraldehyde/PBS for 10 min at room temperature. The activity of the b-galactosidase reporter gene was detected by application of X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) in PBS solution containing magnesium chloride, potassium ferricyanide, and potassium ferrocyanide, according to the instructions provided by the manufacturer (Sigma). Cells expressing the transgene stained an indigo blue that could be identified with brightfield microscopy.
Prostaglandin E 2 ELISA
Cells were plated in 48-well tissue culture plates in serum-free culture medium supplemented with 5 lM arachidonic acid. Following 4-h incubations with test substances, the media were collected and frozen at À808C until assays were performed. Media were analyzed for PGE 2 content by competitive ELISA (Cayman Chemical). Consistent with our prior experience [23, 26, 27] , the intra-and interassay coefficients of variation for this assay were ,10%, and the limit of detection was 15 pg/ml in undiluted samples. When used to compare PGE 2 output from amnion cell subpopulations, each replicate was assayed with a series of dilutions (undiluted, 1:5, 1:10, and 1:20) to accommodate measurements occurring at extremes of the standard curve; those values occurring within the linear range of the standard curve (when plotted logarithmically) were interpreted as being the most accurate.
Statistical Analyses
All experiments in this study were repeated a minimum of three times. ELISA, densitometric, real-time RT-PCR, and luminometric data were assessed by one-way analysis of variance, followed by the Bonferroni multiple comparisons post hoc test, by means of Prism version 4.00 software (GraphPad Software, San Diego, CA); P , 0.05 was considered statistically significant.
RESULTS
Amnion Mesenchymal Cells Produce More PGE 2 than Amnion Epithelial Cells In Vitro
The amniotic membrane consists of a single layer of epithelial cells overlying a layer of mesenchymal cells. Although the amnion is generally accepted to be an intrauterine source for PGE 2 [3, 28] , controversy has surrounded the relative contribution of these two cell types to inducible PGE 2 synthesis. Studies by Whittle et al. [20] and Gibb and Sun [29] have highlighted the importance of subepithelial amnion cells in human parturition by demonstrating that the potential for cytokine-induced PTGS2 expression and PGE 2 release by mesenchymal cells greatly exceeds that for epithelial cells.
We revisited this issue by conducting experiments with primary cultures enriched for either of these two cell types. We found that, for equal numbers of plated cells and in the presence of exogenous arachidonic acid, basal PGE 2 release from mesenchymal cells (1260 6 160 pg/ml/4 h, mean 6 SD) was 5-fold higher than induced PGE 2 release from epithelial cells (233 6 71 pg/ml/4 h) (Fig. 1A , P , 0.001). In the presence of IL1B, a 3-fold increase in mean PGE 2 release from amnion mesenchymal cells (3820 6 730 pg/ml/4 h, P , 0.001) was observed. For amnion epithelial cells, cytokineinduced PGE 2 release was modest (1.4-fold, Fig. 1A , inset) and did not achieve the level of statistical significance in limited experiments.
In primary cultures, amnion mesenchymal cells were identified with vimentin immunolabeling, whereas epithelial cells were recognized by with anti-cytokeratin antibodies [21, 29] . Although both epithelial and mesenchymal cells were found in all amnion cell cultures, the majority (.90%) of cells in five individual mesenchyme-enriched preparations exhibited strong vimentin-like immunostaining, similar to that shown in Figure 1B .
On the basis of these results, we chose amnion mesenchymal cells as a relevant model system in which to focus the remainder of our experiments.
Cytokine-Induced Activation of the Canonical NFjB Signaling Pathway in Amnion Mesenchymal Cells
The general framework for canonical (or classical) NFjB activation is well established [30, 31] . In quiescent cells, a majority of NFjB resides in the cytoplasm coupled with inhibitor (IjB) proteins. In response to a variety of extracellular signals, an IjB kinase complex (IKK) is transiently activated [30, 31] , which, in turn, phosphorylates IjB proteins, evoking a mechanism that ultimately results in proteolytic degradation of this inhibitor. Once liberated from IjB, NFjB translocates to the cell nucleus, where it modulates transcription. To characterize the kinetics of NFjB pathway activation in amnion mesenchymal cells, we conducted a series of time course experiments. Following IL1B challenge, we observed that the alpha and beta subunits of IjB kinase complex IKK (CHUK and IKBKB, respectively) were rapidly but transiently phosphorylated ( Fig. 2A) , a posttranslational event associated with increased IKK complex activity. IKK complex activation was substantiated by the concomitant phosphorylation of NFKBIA (IjBa at serinyl residue 32, which immediately preceded its degradation [between 15 and 30 min]). By 60 min, NFKBIA (IjBa) reappeared, likely the result of rapid de novo resynthesis (as NFKBIA is highly induced by NFjB). A second IKK complex substrate, NFKBIB (IjBb), was degraded with delayed kinetics relative to NFKBIA (IjBa). Nuclear translocation of NFjB was confirmed with immunofluorescence ( Fig. 2B , identified by changes in cellular distribution of RELA [p65] immunoreactivity [23, 27] ). At the same time, signalcoupled phosphorylation of RELA (p65) at serinyl residue 536 was observed (Fig. 2A) ; this latter event, also mediated by the IKK complex, is associated with enhanced NFjB transcriptional activity [30] . Despite resynthesis of NFKBIA (IjBa), net RELA (p65) immunostaining remained nuclear through the 60-min time point. Given that inhibitors such as NFKBIB (IjBb) or NFKBIE (IjBe) are degraded more slowly than NFKBIA (IjBa following cytokine stimulation (reviewed in [30] and [32] ), this finding may reflect that certain pools of RELA (p65)-containing NFjB:IjB protein complexes exhibit delayed nuclear translocation. Overall, these results were highly consistent with those of Yan et al. [21] , who observed that IL1B-induced NFjB binding activity in amnion mesenchymal cells was maximal 1 h following stimulation.
Blockade of NFjB Signaling Attenuates Cytokine-Induced PTGES Expression
The NFjB signaling pathway has been shown to mediate PTGES induction in response to IL1B in pulmonary A549 cells [33] . To determine whether NFjB serves an analogous role in amnion mesenchymal cells, we examined the effect of MG-132, an indirect NFjB inhibitor, on basal-and cytokineinduced PTGES protein expression. In these experiments, amnion cells were preincubated for 30 min with MG-132 or vehicle and then incubated for 4 h with either IL1B or TNF. By immunofluorescence, we confirmed that MG-132 prevented IL1B-induced nuclear translocation of the NFjB subunit RELA (p65) (Fig. 3A) .
Following exposure to either cytokine, PTGES protein expression was increased ;2-fold (Fig. 3, B and C) . In the presence of MG-132, cytokine-elicited PTGES induction was blocked. Under identical treatment conditions, cytokine challenge increased PTGS2 expression by 3-to 6-fold following TNF and IL1B treatment, respectively (Fig. 3, B  and D) . Unexpectedly, rather than blocking PTGS2 induction, MG-132 exposure resulted in a 5-fold increase in PTGS2 protein relative to control. Notably, this occurred even in the absence of cytokine exposure. By comparison, we observed no changes in the levels of PTGES2 or PTGES3 proteins with cytokine or MG-132 treatments (Fig. 3, B , E, and F).
We next examined the effect of MG-132 on PTGES mRNA expression by real-time RT-PCR. As in the prior series of experiments, cells were preincubated for 30 min with MG-132 or vehicle and then challenged for 4 h with cytokine (IL1B) prior to RNA extraction. As shown in Figure 4A , PTGES 
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expression increased by an average of 5-fold (P , 0.05) in response to IL1B. MG-132 significantly decreased induced, as well as basal, PTGES mRNA levels. Under the same conditions, PTGS2 mRNA levels increased robustly (120-fold, P , 0.001) following IL1B (Fig. 4B) . In contrast to its effect on PTGS2 protein expression, MG-132 attenuated PTGS2 induction by 50%. Neither PTGES2 expression (Fig. 4C) nor that of PTGES3 (Fig. 4D ) was significantly altered under these treatment conditions. Similar results were obtained with a cellpermeable peptide inhibitor of NFjB nuclear import, SN50. This second compound, but not an equivalent amount of control SN50M peptide, blocked IL1B-induced PTGES mRNA expression ( Fig. 4E, P , 0.001) .
Given the potential for nonspecificity when pharmacological NFjB inhibitors are used [34] , we performed additional experiments with a dominant-negative variant of human NFKBIA (IjBa). This construct, harboring a serine-to-alanine substitution at amino acid 32, is resistant to phosphorylationinduced degradation and acts by sequestering the cytoplasmic NFjB pool in a manner that is insensitive to extracellular stimuli. Given the relatively low transfection efficiency (10%-30%) of the primary cultures with lipidic reagents, it was necessary to employ adenovirus-mediated gene transfer to achieve levels of expression relevant for use of this construct. In pilot experiments with Ad-lacZ, it was determined that infection at an MOI of 500 resulted in .85% transduction efficiency in amnion mesenchymal cells; however, this was observed only in the presence of ViraDuctin (Fig. 5A) , indicating that amnion mesenchymal cells do not express the coxsackievirus and adenovirus receptor (required for adenoviral infectivity in this case) in abundance [35] . Following transduction with the dominant-negative adenoviral vector (Ad-DN-NFKBIA, we verified that the recombinant protein was resistant to proteasome-mediated degradation following cytokine challenge (Fig. 5B) . By real-time RT-PCR, we found Real-time RT-PCR was used to assess PTGES (E) and PTGS2 (F) expression in amnion mesenchymal cells following treatment with IL1B (10 ng/ml) alone or with 150 lg/ml of either SN50 or SN50M. For each set of experiments, the threshold cycle (C T ) at which each mRNA species was detected was normalized to that of GAPDH. The fold-change in transcript expression was calculated in relation to the control group for individual assays (mean 6 SEM, n ¼ 3 independent experiments). Values in each column with different letters differ significantly, P , 0.05 (ANOVA).
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that both IL1B and TNF significantly increased PTGES expression in cells infected with Ad-lacZ (P , 0.05). Consistent with the results obtained with pharmacological agents, PTGES induction by either cytokine was blocked in cells expressing dominant-negative NFKBIA (Fig. 5C) . Simultaneously, Ad-DN-NFKBIA infection resulted in a 67% decrease in PTGS2 expression following IL1B stimulation relative to cells infected with Ad-lacZ. A similar trend (which did not reach a level of statistical significance) was observed following TNF challenge. Collectively, these data suggest that NFjB contributes to the coordinate regulation of PTGS2 and PTGES but does not influence the expression of PTGES2 or PTGES3.
Identification of a jB-Like Response Element Within the Human PTGES Gene Promoter
Several potential transcriptional elements have been identified in the 5 0 -promoter region of the human PTGES gene, including GC boxes (involved in regulation by the early growth response gene-1 [EGR1] transcription factor); activator protein-1 (AP-1) response elements; CCAAT/enhancer-binding protein a and b biding sites (c/EBPa and b); and response elements for progesterone and glucocorticoid nuclear receptors [9, 36] . Despite data supporting the involvement of NFjB in PTGES transcriptional activation [33] , there has been no evidence that its gene promoter contains a functional jB binding site. We therefore used the TESS (Transcription Element Search Software; http://www.cbil.upenn.edu/tess [37] ) program to identify potential NFjB response elements (jBRE) within the PTGES 5 0 -promoter sequence. One region, located À542/À533 upstream of the PTGES transcription start site and bearing the sequence 5 0 -GAAAAGTCCC, was identified as having a high likelihood for NFjB binding. In the complementary direction, this sequence shares 90% identity with the canonical NFjB Benhancer sequence, 5 0 -GGGRNYYYCC (where R is a purine, Y is a pyrimidine, and N is any nucleic acid) [30] . In the forward direction, this sequence more closely resembles NFjBlike sites that diverge from consensus, such as those found in the 5 0 -promoter regions of cytokine/chemokine genes such interleukin-2 (IL2) [38] and interleukin-8 (IL8) [39] , as well as several apoptosis-related genes [40, 41] .
To examine the effect of IL-1b on PTGES-promoter activity, cells were transiently transfected with a luciferase reporter plasmid containing a segment (À597/þ33 in relation to the transcription start site) of the human PTGES gene promoter (pGL2-651). IL-1b elicited a 2.8-fold increase in reporter activity relative to untreated cells (P , 0.01; Fig. 6B ), confirming the presence of cytokine-responsive transcriptional elements within this promoter region. We additionally observed that this cytokine-induced increase in promoter activity was blocked in the presence of MG-132 (Fig. 6B) , providing further evidence that NFjB contributes to the transcription activation of this gene.
Next, to determine whether the putative jB binding site in the PTGES promoter might correspond to the functional regulation of PTGES in response to IL-1b, site-directed mutagenesis was used to introduce five-point mutations within this sequence (5 0 -tAcAAGaCag, where lowercase letters refer to mutated oligonucleotides). As shown in Figure 6C , responsiveness of the PTGES promoter to cytokine stimulation was diminished when this potential regulatory element was altered.
DISCUSSION
Although the molecular mechanisms responsible for human parturition remain incompletely understood, there is abundant evidence to suggest that inflammation plays an important role in this process (reviewed in [4, 42] ). Concentrations of cytokines, chemokines, and inflammatory lipids increase in amniotic fluid toward term in normal pregnancies (reviewed in [43] ). In addition, during spontaneous active labor, there is significant upregulation in the expression of proinflammatory mediators within intrauterine tissues [44, 45] . Many of these labor-associated genes are regulated at the transcription level by NFjB. The contribution of NFjB to human labor has been addressed by several groups (see [46, 47] for recent reviews), and although biochemical [48] and immunohistochemical [49] studies have been conflicting, the present consensus suggests that NFjB activation both precedes and accompanies parturition. Real-time RT-PCR was used to assess PTGES (C) and PTGS2 (D) mRNA expression in amnion mesenchymal cells following infection either with Ad-lacZ (control, white bars) or Ad-DN-NFKBIA (black bars) for 72 h, followed by treatment with media alone, IL1B (10 ng/ml), or TNF (25 mg/ml) for 4 h. For each set of experiments, the threshold cycle (C T ) at which each mRNA species was detected was normalized to that of GAPDH. The fold-change in transcript expression was calculated in relation to the control group (mean 6 SEM, n ¼ 2 independent experiments). Values in each column with different letters differ significantly, P , 0.05 (ANOVA).
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Prior reports have established the importance of NFjB in regulating PTGS2 expression in amnion and myometrial cells [21, 48, 50] . In the present study, we provide further evidence that NFjB contributes significantly, albeit not exclusively, to cytokine-mediated PTGS2 induction. One unanticipated observation was that MG-132, rather than blocking PTGS2 induction, resulted in a 5-fold increase in the PTGS2 protein level (even in the absence of stimulation). Such results were inconsistent with the abrogating effect of MG-132 on PTGS2 mRNA induction (Fig. 5B) . It is reasonable to speculate that MG-132, an inhibitor of the 26 S proteasome complex, interferes with tonically active PTGS2 protein degradation. Consistently, Mbonye et al. [51] recently demonstrated that normal PTGS2 turnover is mediated through an endoplasmic reticulum-associated degradation system that is ultimately dependent on proteasome-mediated destruction.
In addition to PTGS2, we provide evidence that NFjB contributes to cytokine-induced PTGES gene expression in amnion mesenchymal cells in vitro. In support of this, we observed that pharmacological inhibition of NFjB signaling significantly attenuated cytokine-elicited PTGES mRNA (Fig. 4 , A and E) and protein (Fig. 3D) expression. Similarly, overexpression of a dominant-negative variant of human NFKBIA (IjBa) blocked the induction of PTGES mRNA expression by IL1B and TNF (Fig. 5E) . Furthermore, NFjB inhibitors reduced cytokine-responsive PTGES promoter activity (Fig. 6B) . Although MG-132 also significantly decreased PTGES mRNA expression in the absence of stimulation (Fig. 4A) , suggesting that basal NFjB activity contributes to PTGES expression in resting cells, this effect was not replicated with a second NFjB inhibitor (SN50) or the dominant-negative construct; as such, we cannot discount that off-target activity might have contributed to this effect. Overall, these results are consistent with the observations of Catley et al. [33] , who also used a dominant-negative construct to demonstrate that intact NFjB signaling was required for cytokine-induced PTGES transactivation in A549 cells.
Given that NFjB transcriptional regulation requires the presence of cognate enhancer elements, we used a bioinformatics search algorithm to discern potential jB binding sites within the human PTGES gene promoter. One such region was identified that, when altered by site-directed mutagenesis, significantly decreased cytokine-elicited activation of a segment of the PTGES promoter (Fig. 6C) . Although it remains to be determined which NFjB subunits might bind to this site, these current data are the first to suggest that this region represents an important PTGES regulatory element. It is noteworthy that the PTGES jB-like sequence is similar to a jBRE described previously within the IL8 gene promoter [39] . By introducing point mutations (similar to those described herein) into the IL8 jBRE, Elliott et al. [52] found this region to be important for IL1B-stimulated gene expression in amnion epithelial cells. It is interesting that the jB response elements in these two genes, as well as those in several other cytokine and chemokine promoters [38, 40, 41] , share sequence similarity that differs from the traditional jBRE consensus sequence [30] . Inasmuch as prior and current evidence supports the functionality of such ''variant'' jBREs, we speculate that the jB-like motif in the PTGES promoter is likely to represent a bona fide NFjB response element.
In addition to NFjB, PTGES and PTGS2 may share coordinate regulation through other means. Indeed, both PTGS2 and PTGES genes contain multiple transcription factor binding motifs, and it is likely that combinatorial control of these transcripts contributes to their optimal expression. For example, effectors of the mitogen-activated protein kinase 1 (MAPK1, p38) could contribute to the coinduction of PTGS2 [27, 53] and PTGES [54] . In PTGES, such effects might manifest directly or via the induction of an intercessor (early growth response gene-1 [EGR1], another master gene regulator whose product transactivates the PTGES promoter [55] ). EGR1 may act either cooperatively [56] or antagonistically [57] with NFjB (depending on context), and limited evidence additionally suggests that the EGR1 gene itself is regulated by NFjB [58] . How such nonlinear interactions might contribute to the regulation of PTGES expression remains to be determined. In light of the potential for combinatorial regulatory control, it is somewhat surprising that inhibition of the NFjB pathway had such a pronounced effect on PTGES induction in the current study. We cannot completely discount that the pharmacological inhibitors (or perhaps even the dominant-negative construct) acted through the blockade multiple-signaling pathways, contributing to the dramatic reduction in cytokine-mediated PTGES expression that we have attributed to NFjB. Nor did we anticipate that point mutations in a single putative response element would so significantly decrease cytokine-elicited PTGES promoter activation. Nevertheless, our results provide compelling evidence that the transcriptional control of PTGES warrants additional scrutiny.
Inasmuch as prior reports have suggested that labor has little, if any, effect on the expression of PTGES [59, 60] , it would appear that PTGES induction is not rate limiting for PGE 2 synthesis in fetal membranes during parturition. Therefore, it is unclear to what extent upregulation, rather than mere presence, of PTGES contributes to this process. Although it is difficult to reconcile our own in vitro data, and those of others [13, 14] , to the in vivo context of labor, our results suggest that coordinate regulation of PTGS2 and PTGES facilitates cytokine-elicited PGE 2 production within amnion mesenchymal cells. It may be possible to infer that a similar, albeit more complicated, molecular mechanism governs the synthesis of PGE 2 within the intact amniochorion and decidua.
